Neltenexine | 99453-84-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Neltenexine
• 英文别名: N-[2,4-dibromo-6-[[(4-hydroxycyclohexyl)amino]methyl]phenyl]thiophene-2-carboxamide
• CAS: 99453-84-6
• 化学式: C₁₈H₂₀Br₂N₂O₂S
• 分子量: 488.2
• InChiKey: SSLHKNBKUBAHJY-UHFFFAOYSA-N

物化性质

• 沸点：
  515.5±50.0 °C(Predicted)
• 密度：
  1.69±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  89.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Compound having antibronchopneumopathic activity, process for its preparation and pharmaceutical compositions containing it
  申请人：PULITZER ITALIANA S.p.A.

  公开号：EP0150787A2

  公开（公告）日：1985-08-07

  4-[[(2-(2-Thenoyl)amino-3,5-dibromophenyl)-methyl]-amino]cyclohexanol of formula (I): and pharmaceutically acceptable acid addition salt thereof have been found to have valuable therapeutic properties. Compound (I) may be prepared by reacting 4-[[(1-amino-3,5-dibromophenyl)-methyl]amino]cyclohexanol with thenoyl chloride.

  式 (I) 的 4-[[(2-(2-噻吩甲酰)氨基-3,5-二溴苯基)-甲基]-氨基]环己醇： 及其药学上可接受的酸加成盐具有宝贵的治疗特性。 化合物 (I) 可通过 4-[[(1-氨基-3,5-二溴苯基)-甲基]氨基]环己醇与酰氯反应制备。
• Therapy and kit for the prevention and treatment of cystic fibrosis
  申请人：Trustees of Dartmouth College

  公开号：US10744180B2

  公开（公告）日：2020-08-18

  Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.

  本研究提供了用于预防或治疗囊性纤维化的组合物、试剂盒和方法，其中包括使用一种抑制 CAL 蛋白和突变 CFTR 蛋白之间相互作用的拟肽物。
• Dab2 inhibitors for the prevention and treatment of cystic fibrosis
  申请人：Trustees of Dartmouth College

  公开号：US10864248B2

  公开（公告）日：2020-12-15

  Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti-inflammatory agent or a combination thereof are provided as are methods for preventing or treating cystic fibrosis.

  提供的组合物和试剂盒包括一种抑制禁用-2和突变型CFTR蛋白之间相互作用的制剂，可选择与CFTR校正剂、CFTR增效剂、CAL抑制剂、粘液溶解剂、抗炎剂或其组合物结合使用，以及预防或治疗囊性纤维化的方法。
• Compositions and methods for the treatment of cystic fibrosis
  申请人：RDG Holdings, Inc.

  公开号：US11116791B2

  公开（公告）日：2021-09-14

  Disclosed herein are methods and compositions for treating, inhibiting, or ameliorating pulmonary infections, including cystic fibrosis. Aspects described herein relate to compositions including a saline solution and hypochlorite and methods of using these compositions alone or in combination with additional compounds, including antibiotics, an anti-inflammatories, bronchodilators, mucolytics, or oxygen therapy for treating, ameliorating, or inhibiting a pulmonary infection, including cystic fibrosis.

  本文公开了治疗、抑制或改善肺部感染（包括囊性纤维化）的方法和组合物。本文描述的方面涉及包括生理盐水和次氯酸盐的组合物，以及单独使用这些组合物或与其他化合物（包括抗生素、消炎药、支气管扩张剂、粘液溶解剂或氧疗法）结合使用以治疗、改善或抑制包括囊性纤维化在内的肺部感染的方法。
• COMBINATION THERAPY AND KIT FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS
  申请人：TRUSTEES OF DARTMOUTH COLLEGE

  公开号：US20140100155A1

  公开（公告）日：2014-04-10

  A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.